Will Abraxane join the new gang of melanoma fighters? The Celgene ($CELG) drug, a reformulated version of the chemo drug paclitaxel, kept the cancer at bay for longer than the standard chemotherapy, dacarbazine, a new study found. That may or may not be enough to put Abraxane into the mix with Bristol-Myers Squibb's ($BMY) Yervoy and Roche's ($RHHBY) targeted melanoma drug Zelboraf. Report